Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Zirwas

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 21, 2018
ParabensAnthony F Fransway, Paulina J Fransway, Donald V Belsito, et al.
Dermatology and Therapy|January 19, 2026
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt StudyJonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the American Academy of Dermatology|March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trialLinda Stein Gold, David N Adam, Lorne Albrecht, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|December 21, 2018
ParabensAnthony F Fransway, Paulina J Fransway, Donald V Belsito, et al.
Dermatology and Therapy|January 19, 2026
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt StudyJonathan I Silverberg, Lindsay Ackerman, Jerry Bagel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension studyMatthias Augustin, Marie Tauber, Robert Sidbury, et al.
Journal of the American Academy of Dermatology|March 31, 2024
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trialLinda Stein Gold, David N Adam, Lorne Albrecht, et al.
JAMA|September 20, 2022
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical TrialsMark G Lebwohl, Leon H Kircik, Angela Y Moore, et al.
Pageof 8